Eon Labs Receives Final Approval for Citalopram HBr Tablets and Will Begin Shipping Immediately.LAURELTON, N.Y. -- Eon Labs, Inc. (Nasdaq: ELAB Elab is a village in the state of Ngaraard, and it is north of the villages of Ngebuked and Ulimang. It is the home to Ngaraard's only private christian (Protestant) high school, Bethania Girl's High School in Ngesang, a small portion of Elab village. ) announced today that it received final approval for Citalopram citalopram /ci·tal·o·pram/ (si-tal´o-pram) 1. an antidepressant compound used in the treatment of major depressive disorder, administered orally as the hydrobromide. 2. HBr, the generic equivalent of Celexa Ce·lex·a A trademark for the drug citalopram hydrobromide. citalopram hydrobromide Celexa Pharmacologic class: Selective serotonin reuptake inhibitor Therapeutic class: (R)(a) tablets, in the same strengths as the brand, 10mg, 20mg and 40mg. The introduction of Citalopram HBr represents another first to market product for Eon Labs. The Company will begin shipping Citalopram HBr tablets immediately. Eon Labs is a generic pharmaceutical company specializing in developing, licensing, manufacturing, selling and distributing a broad range of prescription pharmaceutical products. For press releases and other company information, visit the Eon Labs, Inc. website at www.eonlabs.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement under the U.S. Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. . These factors and additional information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. (a)Celexa(R) is a registered trademark of Forest Pharmaceuticals, Inc. which is not affiliated with Eon Labs, Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion